An article from UniQure falls further on Makary comments Remarks the FDA commissioner made during a CNBC appearance seemed to stoke investor fears that UniQure’s gene therapy for Huntington’s won’t get approved. Published Feb. 27, 2026 Jacob Bell Lead Reporter Share Copy link Email LinkedIn X/Twitter Facebook Print License
